Overview

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

Status:
Completed
Trial end date:
2016-01-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and activity of the combination of lenalidomide with intermediate dose dexamethasone and cyclophosphamide in patients with primary systemic (AL ) amyloidosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Athens
Collaborator:
Hellenic Cooperative Oncology Group
Treatments:
BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide